LabCorp and its Specialty Testing Group, a fully integrated portfolio of specialty and esoteric testing laboratories.

Lipid Profile, Nonfasting, Pediatric

CPT: 82465; 83718
Updated on 11/4/2020
Print Share

Test Includes

Cholesterol, total; high-density lipoprotein (HDL); non-HDL cholesterol (calculated as total cholesterol minus HDL)

Special Instructions

State patient's age and sex on the test request form.

Expected Turnaround Time

Within 1 day

Related Documents

For more information, please view the literature below.

Clinical Lipid Panel Selection Table

For more information, please view the literature below.

Clinical Lipid Panel Selection Table

Specimen Requirements


Serum (preferred) or plasma


2 mL

Minimum Volume

0.5 mL


Gel-barrier tube, green-top (heparin) tube, or lavender-top (EDTA) tube


Separate serum or plasma or from cells within 45 minutes of collection.

Storage Instructions

Maintain specimen at room temperature. Stable at room temperature, refrigerated or frozen for seven days.

Patient Preparation


Causes for Rejection


Test Details


Assessment of cardiovascular health and risk stratification in pediatric, adolescent, and young adult populations.


Patients with obstructive liver disease may develop lipoprotein abnormalities.



Additional Information

Atherosclerosis begins in youth, and this process, from its earliest phases, is related to the presence and intensity of the known cardiovascular risk factors. Clinical events such as myocardial infarction, stroke, peripheral arterial disease, and ruptured aortic aneurysm are the culmination of the lifelong vascular process of atherosclerosis. The most important evidence relating risk in youth to clinical CVD is the observed association of risk factors for atherosclerosis to clinically manifest cardiovascular conditions. Genetic disorders related to high cholesterol are the biological model for risk-factor impact on the atherosclerotic process. Combined evidence from autopsy studies, vascular studies, and cohort studies strongly indicates that abnormal lipid levels in childhood are associated with increased evidence of atherosclerosis. The evidence review supports the concept that early identification and control of dyslipidemia throughout youth and into adulthood will substantially reduce clinical CVD risk beginning in young adult life. Significant evidence exists to indicate that using family history of premature CVD or cholesterol disorders as the primary factor in determining lipid screening for children misses ~30% to 60% of children with dyslipidemias, and accurate and reliable measures of family history are not available. In the absence of a clinical or historic marker, identification of children with lipid disorders that predispose them to accelerated atherosclerosis requires universal lipid assessment. Non-HDL cholesterol level has been identified as a significant predictor of the presence of atherosclerosis, as powerful as any other lipoprotein cholesterol measure in children and adolescents. For both children and adults, non-HDL cholesterol level seems to be more predictive of persistent dyslipidemia and, therefore, atherosclerosis and future events than TC, LDL cholesterol, or HDL cholesterol levels alone. A major advantage of non-HDL cholesterol is that it can be accurately calculated in a nonfasting state and is, therefore, practical to obtain in clinical practice.1


1. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: Summary report. Pediatrics. 2011 Dec; 128(Suppl 5):S213-S256.22084329


Order Code Order Code Name Order Loinc Result Code Result Code Name UofM Result LOINC
373634 Ped Lipid Panel, Non-Fasting 001065 Cholesterol, Total mg/dL 2093-3
373634 Ped Lipid Panel, Non-Fasting 011817 HDL Cholesterol mg/dL 2085-9
373634 Ped Lipid Panel, Non-Fasting 011976 Non-HDL Cholesterol mg/dL 43396-1
373634 Ped Lipid Panel, Non-Fasting 011836 Comment: N/A
373634 Ped Lipid Panel, Non-Fasting 012029 Comment 77202-0

For Providers

Please login to order a test

Order a Test

© 2020 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.

CPT Statement/Profile Statement

The LOINC® codes are copyright © 1994-2020, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at Additional information regarding LOINC® codes can be found at, including the LOINC Manual, which can be downloaded at